linjc16/ctgov huggingface dataset:
Effect of Daily Stair Walking on Cardiovascular Health

Study Overview
=================
Brief Summary
-----------------
Many adults find it difficult to perform physical exercise during leisure. The workplace may provide an optimal setting to encourage a healthier lifestyle. This study investigates the effect of daily stair walking at the workplace on cardiovascular health. The main hypothesis is that daily stair walking for 10 weeks compared with a control group results in increased aerobic fitness.

Official Title
-----------------
Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace

Conditions
-----------------
Cardiovascular Health

Intervention / Treatment
-----------------
* Behavioral: Stair walking


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: office worker Exclusion Criteria: life threatening disease pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stair walking<br>Participants of this group is encouraged to use the stairs for 10 minutes a day at the workplace | Behavioral: Stair walking<br>* Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active<br>|
| Active Comparator: Control<br>Receives a health examination before and after the intervention period, and are advised to stay active | Behavioral: Stair walking<br>* Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aerobic fitness | Watt-max test on a Monark bicycle ergometer | before and after the 10 week intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure |  | before and after the 10 week intervention | 
| Questionnaire-based data | working conditions, perceived health, tiredness and energy, physical activity | before and after the 10 week intervention | 
| Heart Rate Variability | HRV during rest is measured during a standardized test (5 min supine, 5 minute upright, 5 minute supine) | Before and after the 10 week intervention |
BPA Levels Relationship With IVF/ICSI Outcomes in Patients With Male Factor

Study Overview
=================
Brief Summary
-----------------
Association between blood and semen BPA levels and ICSI outcomes in patients with male factor

Official Title
-----------------
Impact of Blood and Ejaculate Bisphenol A Concentrations on ICSI Cycles Outcome in Patients With Male Factor

Conditions
-----------------
IVF, Infertility, Male

Intervention / Treatment
-----------------
* Other: BPA levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female patients aged 23-40 years who underwent IVF due to male factor men with semen sample obtained from ejaculate male patients provided blood, and ejaculate samples on the oocyte retrieval day patients who did not smoke or use alcohol patients did not work in the plastic industry Exclusion Criteria: men with a diagnosis of azoospermia patients who underwent IVF due to low ovarian reserve or unexplained infertility indications patients diagnosed with endometriosis patients with freeze-all cycles women with metabolic disease (such as hypertension or diabetes mellitus) patients (male or females) with a known genetic problem (male or female)

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: BPA level<br>BPA (Bisfenol A) in blood and ejaculate samples | Other: BPA levels<br>* BPA (Bisfenol A) in blood and ejaculate samples<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exposure to BPA | Concentrations of Bisphenol A (BPA) will be quantified in the blood plasma, and ejaculate (individual and pooled samples) by use of ELİSA test in women with male factor | 6 month |
Randomized Trial of Prehospital Tropin Levels in Acute Coronary Syndrome (ACS)

Study Overview
=================
Brief Summary
-----------------
This study randomizes patients seen by Redmond Medic One into a control arm and a study arm when they present with acute coronary syndrome and have non-contributory ECG's (i.e.non-STEMI). The control group is treated normally and delivered to the receiving hospital. The study group is treated normally as well, however troponin measurements are made using an i-STAT blood analyzer prior to hospital arrival. The results are presented to the receiving physician. Door-to-reperfusion time is monitored for both groups.

Official Title
-----------------
Randomized Trial of Prehospital Troponin Assessment Using the i-STAT Blood Analyzer

Conditions
-----------------
Acute Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over years of age ACS without ST-segment elevation Patient being transported to one of two participating hospitals Exclusion Criteria: Less then 18 years of age. Post cardiac arrest. ACS with ST-segment elevation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Group<br>Troponin measured prior to hospital arrival | |
| Control Group<br>Patients transported to hospital without troponin measurements enroute | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease door-to-reperfusion time for patients with non-STEMI's by measuring troponin levels prior to hospital arrival |  | 3-4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non STEMI, ACS, ECG troponin, iSTAT, Acute coronary syndrome without ST-segment elevation
Consultation in the Emergency Department

Study Overview
=================
Brief Summary
-----------------
This study intends to evaluate consultation in the Emergency Department. The purpose is to demonstrate that standardizing communication in the Emergency Department may lead to improved consultation.

Official Title
-----------------
A Prospective, Randomized Controlled Study Demonstrating a Novel, Effective Model of Communication Among Physicians: The 5 Cs of Consultation

Conditions
-----------------
Communication

Intervention / Treatment
-----------------
* Behavioral: 5 Cs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency medicine residents (PGY1-5) Exclusion Criteria: Did not want to partake in the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 5 Cs<br>Educational intervention | Behavioral: 5 Cs<br>* education on consultation<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Consultation effectiveness as measured by global rating scale | A global rating scale will be used to measure effectiveness of the intervention. | Up to 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Consultation effectiveness as determined by a Checklist rating | The checklist will be based off of the educational intervention, the 5 Cs, and the global rating scale will be based on expert assessment. | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
consultation
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.

Official Title
-----------------
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1

Intervention / Treatment
-----------------
* Drug: insulin detemir
* Drug: insulin glargine
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 diabetes for at least 12 months Current treatment with basal-bolus insulin regimen for more than or equal to 3 months HbA1c less than or equal to 11.0% Exclusion Criteria: Proliferative retinopathy or maculopathy Recurrent major hypoglycaemia Impaired hepatic or renal function Cardiac problems or uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: insulin detemir|nan|
|Drug: insulin glargine|nan|
|Drug: insulin aspart|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | after 1 year trial period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  |  | 
| Body weight |  |  | 
| Hypoglycemia |  |  | 
| Blood glucose |  |  | 
| Insulin Treatment Satisfaction |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Mellitus, Type I
Vitamin D Levels and Vitamin D Education in Geriatric Patients

Study Overview
=================
Brief Summary
-----------------
Vitamin D is important to maintain good health. Although it is found in foods and vitamins, many people still have low vitamin D levels. One purpose of this study is to describe vitamin D levels from patients at the University of Colorado Seniors Clinic. Another goal of the study is to find out if education by a pharmacist can increase vitamin D levels in patients who have low vitamin D levels.

Official Title
-----------------
Characterization of Vitamin D Levels and Affect of Pharmacist-initiated Vitamin D Education in Geriatric Outpatients.

Conditions
-----------------
Vitamin D Insufficiency, Vitamin D Deficiency

Intervention / Treatment
-----------------
* Behavioral: Pharmacist Education about Vitamin D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient at the University of Colorado Hospital Seniors Clinic with an appointment in December 2005 or January 2006 Age 65-89 years Exclusion Criteria: History of dementia or memory loss Severe illness or life expectancy less than 6 months Assistance with medications from an assisted living facility History of celiac Sprue, Crohn's disease, or chronic pancreatitis High calcium levels, high parathyroid hormone levels, low phosphorus levels, or very high vitamin D levels Taking prescription vitamin D

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pharmacist education<br>Pharmacist education about vitamin D | Behavioral: Pharmacist Education about Vitamin D<br> <br> |
| No Intervention: Usual care<br>Usual care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 25(OH) vitamin D level | Change in vitamin D level after usual care or pharmacist education | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin D deficiency, geriatric patients
Treatment of Ventilator Associated Pneumonia in Pediatric Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
treatment of ventilator associated pneumonia in pediatric intensive care unit according to the American guidelines

Detailed Description
-----------------
to assess the degree of adherence of pediatric physicians of assiut university children hospital to the American guidelines of treatment of ventilator associated pneumonia in pediatric intensive care unit searching for defects,obstacles,or need to improve health service.

Official Title
-----------------
Treatment of Ventilator Associated Pneumonia in Pediatric Intensive Care Unit

Conditions
-----------------
Ventilator Associated Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Children of both sexes. - Aged from 1 month to 18 years. - The patients are fulfilling the diagnostic criteria of ventilator associated pneumonia. Exclusion Criteria: - Patients aged less than 1 month. - Patients who are intubated and mechanically ventilated for less than 48 hours.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment of ventilator associated pneumonia in pediatric intensive care unit | to assess the quality of care and treatment of ventilator associated pneumonia in pediatric intensive care unit in assiut university children hospital according to the american guidelines and evaluation of the performance of the unit as regard sticking to the guidelines of treatment of VAP | 9 month - 1 year |
Comparative Effects of Post-exercise Ingestion of a High or Low Molecular Weight Solution on Resistance Exercise Performance

Study Overview
=================
Brief Summary
-----------------
This study sought to examine differences in resistance exercise performance, as measured by the kinetic and kinematic profile during multiple sets of the back squat exercise, following ingestion of high or low molecular weight carbohydrate beverages.

Official Title
-----------------
Comparative Effects of Post-exercise Ingestion of a High or Low Molecular Weight Solution on Resistance Exercise Performance

Conditions
-----------------
Task Performance and Analysis

Intervention / Treatment
-----------------
* Dietary Supplement: Vitargo ®, Swecarb AB, Karlskrona, Sweden
* Dietary Supplement: DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA
* Other: Placebo: Water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: having at least 2 years resistance training experience to include the parallel back squat exercise at least once a week no musculoskeletal injury within previous 1 year not having consumed any nutritional or ergogenic supplement excluding protein and/or a daily vitamin for the previous 6-week period Exclusion Criteria: no previous resistance training experience musculoskeletal injury within the previous 1 year having consumed or presenting consuming a nutritional or ergogenic supplement

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Flavored Water | Other: Placebo: Water<br> <br> |
| Active Comparator: Low Molecular Weight Carbohydrate<br>low molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate | Dietary Supplement: DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA<br> <br> |
| Experimental: High molecular weight carbohydrate<br>high molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate | Dietary Supplement: Vitargo ®, Swecarb AB, Karlskrona, Sweden<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Power Output | Change in power output, measured in watts, will be examined over the course of the performance of 5 sets of 10 repetitions of the back squat exercise with a weight corresponding to 75% one-repetition maximum. | 1 year |
National Survey on Hypertension at Hospital

Study Overview
=================
Brief Summary
-----------------
To evaluate (with sufficient accuracy) the profile(demographic and clinical characteristics, health care management) of hypertensive patients seen in hospital out patient's department by a cardiologist or a nephrologists.

Official Title
-----------------
Profile of Hypertensive Patients Seen in Hospital Outpatient's Department

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Known hypertension agree to take part in this study Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic, clinical and health care characteristics |  | Once |
A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.

Official Title
-----------------
A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout

Conditions
-----------------
Acute Gout

Intervention / Treatment
-----------------
* Drug: MK0663; etoricoxib / Duration of Treatment: 5 Days
* Drug: Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females at least 18 years of age who have acute gout.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0663; etoricoxib / Duration of Treatment: 5 Days|nan|
|Drug: Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient assessment of pain (0- to 4- Likert scale) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Global Assessment of Response to Therapy (0- to 4- point scale) |  |  | 
| Investigator Global Assessment of Response to Therapy (0- to 4- point scale) |  |  | 
| Tenderness of the study joint (0- to 3-point scale) |  |  | 
| Swelling of the study joint (0- to 3-point scale) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arcoxia